Jefferies analyst, Brian Abrahams, noted that RGLS reported RG101, an injectable anti-miR-122 oligo, was placed on clinical hold on a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE